Zimmer, Biomet Sell Off Some U.S. Assets As They Finalize A $14 Bil. Merger
This article was originally published in The Gray Sheet
Executive Summary
Zimmer Biomet is now the second-largest orthopedic device maker behind Johnson & Johnson now that the merger between the two firms is complete. The companies divested some U.S. knee, elbow and bone cement assets in conjunction with finalized the deal after having sold of some European assets earlier in the year.
You may also be interested in...
Mexico’s Health Care Agency Alleges Zimmer Fraud
Mexico’s health care agency is suing Zimmer Biomet for a refund on purchases it made from the company during a long-running bribery scheme. The agency claims the bribery, which was admitted in a 2017 settlement with the US government, nullified its contracts with the device maker.
Market Intel: EU Ortho Close-Up: Rising, But Varying Orthopedic/Spinal Opportunities In 5 European Markets
A rising and more active aging population, and a growing incidence of osteoporosis fractures and back pain – as well as other spine-related issues – are paving the way for companies to bring innovative devices into the hands of orthopedic and spinal surgeons in Spain, Italy, Germany, the UK and France. In this feature, we take a closer look at the prevailing surgical approaches and techniques for selected fracture fixation, spinal surgery procedures, joint replacement, and arthroscopy procedures in each of the five major EU countries, as outlined in a new Meddevicetracker report. We also take a deep dive into the various growth opportunities of select procedures in each EU market and discuss trends.
Earnings Winners and Losers: JNJ, MMSI, ABT, ZBH, SNN, EW, Plus Round-Up
Among the medtech companies who have released their first-quarter 2017 sales and earnings, Johnson & Johnson and Merit Medical Systems reported progress in their long-term plans to reshape their medical device businesses, while Abbott and Zimmer Biomet received some bad news in the quarter. Smith & Nephew shows signs of a turnaround, and perennial "winner" Edwards Lifesciences provided updates on some important developments in their flagship transcatheter valve business.